Retatrutide has moved beyond early-stage clinical research into a broad Phase 3 development program. Results reported in 2026 have increased scientific interest because multiple trials have reported substantial changes in body weight and other metabolic measures. But Phase 3 results still need to be interpreted carefully. Some 2026 findings have been released as topline company results and are awaiting detailed peer-reviewed publication. Retatrutide also remains investigation

Retatrutide has attracted significant attention because early clinical research produced substantial changes in body weight. Understanding those results requires looking at how the trial was designed, who participated, what researchers measured, and what the study could not establish. The pivotal Phase 2 study was a randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine. It evaluated retatrutide in 338 adults with obesity or overwe